Showing results (191-200 of 237) with videos related to

Sort By:
Pageof 24
Investigational New Drugs|September 1, 2005
An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicinH Hirte, D Stewart, R Goel, et al.
Biochemistry|December 7, 1993
Structure/function studies of HIV-1(1) reverse transcriptase: dimerization-defective mutant L289KR Goel, W A Beard, A Kumar, et al.
The Journal of Experimental Medicine|March 29, 2018
Microbial symbionts regulate the primary Ig repertoireYuezhou Chen, Neha Chaudhary, Nicole Yang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2001
A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumoursH Hirte, R Goel, P Major, et al.
Investigational New Drugs|November 6, 2004
An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorinR Goel, E Chouinard, D J Stewart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1994
Duration of intravenous antibiotics for patients with neutropenic feverA T Tomiak, J C Yau, S D Huan, et al.
American Journal of Clinical Oncology|December 18, 1998
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancerG A Bjarnason, C Cripps, R Goel, et al.
Oncology Reports|April 4, 1998
Effects of PALA on the pharmacokinetics of 5-fluorouracilM A Nassim, M R Rouini, M C Cripps, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2006
A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials GroupG Goss, L L Siu, I Gauthier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2006
Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115J A Maroun, K Belanger, L Seymour, et al.
Pageof 24